| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
38,620,000 |
| Market
Cap: |
57.16(M) |
| Last
Volume: |
2,036,333 |
Avg
Vol: |
2,030,677 |
| 52
Week Range: |
$1.07 - $3.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CEL-SCI is a clinical-stage biotechnology company focused on research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. Co. is focused on the development of the following product candidates and technologies: Multikine® (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for the potential treatment of certain head and neck cancers; and Ligand Epitope Antigen Presentation System technology, with CEL-4000 as a product candidate under development for the potential treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kersten Geert R |
Chief Executive Officer |
• • – |
2022-06-30 |
4 |
A |
$4.50 |
$4,347 |
D/D |
966 |
1,149,377 |
|
- |
|
| Talor Eyal |
Chief Scientific Officer |
• – – |
2022-03-31 |
4 |
A |
$3.93 |
$2,397 |
D/D |
610 |
105,847 |
|
- |
|
| Kersten Geert R |
Chief Executive Officer |
• • – |
2022-03-31 |
4 |
A |
$3.93 |
$4,347 |
D/D |
1,106 |
1,148,411 |
|
- |
|
| Zimmerman Daniel H |
Senior Vice President |
• – – |
2022-03-31 |
4 |
A |
$3.93 |
$3,954 |
D/D |
1,006 |
118,084 |
|
- |
|
| Prichep Patricia B |
Senior Vice President |
• – – |
2022-03-31 |
4 |
A |
$3.93 |
$4,288 |
D/D |
1,091 |
209,276 |
|
- |
|
| Talor Eyal |
Chief Scientific Officer |
• – – |
2021-12-31 |
4 |
A |
$7.10 |
$2,400 |
D/D |
338 |
105,237 |
|
- |
|
| Kersten Geert R |
Chief Executive Officer |
• • – |
2021-12-31 |
4 |
A |
$7.10 |
$4,345 |
D/D |
612 |
1,147,305 |
|
- |
|
| Prichep Patricia B |
Senior Vice President |
• – – |
2021-12-31 |
4 |
A |
$7.10 |
$4,288 |
D/D |
604 |
208,185 |
|
- |
|
| Zimmerman Daniel H |
Senior Vice President |
• – – |
2021-12-31 |
4 |
A |
$7.10 |
$3,955 |
D/D |
557 |
117,078 |
|
- |
|
| Talor Eyal |
Chief Scientific Officer |
• – – |
2021-10-19 |
4 |
S |
$11.25 |
$168,750 |
D/D |
(15,000) |
104,899 |
|
51% |
|
| Zimmerman Daniel H |
Senior Vice President |
• – – |
2021-09-30 |
4 |
A |
$10.99 |
$3,770 |
D/D |
343 |
116,521 |
|
- |
|
| Talor Eyal |
Chief Scientific Officer |
• – – |
2021-09-30 |
4 |
A |
$10.99 |
$2,396 |
D/D |
218 |
119,899 |
|
- |
|
| Prichep Patricia B |
Senior Vice President |
• – – |
2021-09-30 |
4 |
A |
$10.99 |
$4,088 |
D/D |
372 |
207,581 |
|
- |
|
| Kersten Geert R |
Chief Executive Officer |
• • – |
2021-09-30 |
4 |
A |
$10.99 |
$4,341 |
D/D |
395 |
1,146,693 |
|
- |
|
| Watson Robert Eugene |
Director |
– • – |
2021-07-06 |
4 |
B |
$8.00 |
$10,000 |
D/D |
1,250 |
4,431 |
2.39 |
47% |
|
| Kersten Geert R |
Chief Executive Officer |
• • – |
2021-07-06 |
4 |
B |
$8.00 |
$200,000 |
I/I |
25,000 |
1,146,298 |
2.66 |
47% |
|
| Baillavoine Bruno Jean-Marie |
Director |
– • – |
2021-07-06 |
4 |
B |
$8.00 |
$10,000 |
D/D |
1,250 |
5,973 |
2.39 |
47% |
|
| Zimmerman Daniel H |
Senior Vice President |
• – – |
2021-06-30 |
4 |
A |
$8.68 |
$3,776 |
D/D |
435 |
116,178 |
|
- |
|
| Talor Eyal |
Chief Scientific Officer |
• – – |
2021-06-30 |
4 |
A |
$8.68 |
$2,396 |
D/D |
276 |
119,681 |
|
- |
|
| Prichep Patricia B |
Senior Vice President |
• – – |
2021-06-30 |
4 |
A |
$8.68 |
$4,088 |
D/D |
471 |
207,209 |
|
- |
|
| Kersten Geert R |
Chief Executive Officer |
• • – |
2021-06-30 |
4 |
A |
$8.68 |
$4,349 |
D/D |
501 |
1,121,298 |
|
- |
|
| Young Peter R |
Director |
– • – |
2021-06-28 |
4 |
B |
$12.66 |
$37,971 |
D/D |
3,000 |
28,914 |
2.39 |
-6% |
|
| Cipriano John |
Senior Vice President |
• – – |
2021-04-22 |
4 |
S |
$24.38 |
$243,793 |
D/D |
(10,000) |
63,108 |
|
53% |
|
| Prichep Patricia B |
Senior Vice President |
• – – |
2021-03-31 |
4 |
A |
$15.21 |
$4,091 |
D/D |
269 |
206,738 |
|
- |
|
| Zimmerman Daniel H |
Senior Vice President |
• – – |
2021-03-31 |
4 |
A |
$15.21 |
$3,772 |
D/D |
248 |
115,743 |
|
- |
|
227 Records found
|
|
Page 2 of 10 |
|
|
0.06 (4.23%) 
